
Cancers 2020, 12, 3533 S1 of S2

## Supplementary Materials: First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data From the Medical University Vienna

Barbara Kiesewetter, Ingrid Simonitsch-Klupp, Marius E Mayerhoefer, Werner Dolak, Julius Lukas and Markus Raderer



**Figure S1.** Kaplan-Meier curve for estimated progression-free survival in MALT lymphoma patients treated with immunotherapy versus chemotherapy for further common primary localizations: (**A**) ocular adnexal MALT lymphoma patients; (**B**) pulmonary MALT lymphoma patients; (**C**) parotid gland MALT lymphoma patients. *X*-axis follow-up in months, *Y*-axis cumulative progression-free survival.

Cancers 2020, 12, 3533 S2 of S2

Table S1. Univariate analysis for PFS and OS according to clinical features.

Clinical Features	P-Value PFS	P-Value OS
Age 70+	p = 0.613	p = 0.022
MALT-IPI > 0	p = 0.614	p = 0.119
Gastric versus extragastric	p = 0.196	p = 0.654
Localized versus disseminated	p = 0.163	p = 0.129
Autoimmune disorder	p = 0.078	p = 0.740
LDH > ULN	p = 0.010	p = 0.331
Performance status > 1	p = 0.492	p = 0.024
Plasmacytic diff.	p = 0.912	p = 0.390
Beta2-microglobulin > ULN	p = 0.981	p = 0.010
Paraproteinemia	p = 0.379	p = 0.009
Viral hepatitis	p = 0.211	p = 0.500

Italics indicate significance. *Abbreviations in chronological order:* PFS = progression-free survival; OS = overall survival; MALT = mucosa associated lymphoid tissue lymphoma; IPI = international prognostic index; LDH = lactate dehydrogenase; ULN = upper limit of normal; diff. = differentiation.

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).